2023 Annual Report and Accounts

Oxford Biomedica PLC

30 April 2024

 

Oxford Biomedica

2023 Annual Report and Accounts

Oxford, UK - 30 April 2024: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a quality and innovation-led cell and gene therapy CDMO, gives notice that the 2023 Annual report and accounts is now available on the "Investors" section of the Group's website at www.oxb.com. In accordance with Listing rule 9.6.1, the 2023 Annual report and accounts has also  been submitted to the Financial Conduct Authority for publication through the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

Further copies of the 2023 Annual report and accounts are available from the Company Secretary, Oxford Biomedica plc, Windrush Court, Transport Way, Oxford, OX4 6LT, United Kingdom (telephone number: [phone]). The Company confirms that, in compliance with DTR 6.3.5(1A), the regulated information required under DTR 6.3.5, is available in unedited full text within the Annual Report available on the National Storage Mechanism and in compliance with DTR 6.3.5(3) is available on the Company's website as noted above.

-Ends-

For further information, please contact:
Oxford Biomedica plc: Natalie Walter, Company Secretary	Tel: [phone]

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenoviral vectors, and other viral vector types. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.

 

END